Nanotechnology for the Prevention, Diagnosis, and Therapy of HIV, HCV, and Coinfection: From Bench to Bedside
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 9
Special Issue Editors
Interests: diagnostic; HCV; HIV/HCV coinfection; HIV; infectious diseases; nanomedicine; nanotechnology; prevention; virology
Special Issues, Collections and Topics in MDPI journals
Interests: HIV; hepatitis C; infectious diseases; immunology; virology; genetics; epidemiology; cirrhosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
HIV and HCV continue to be major global health challenges, affecting millions worldwide. While antiretroviral therapy (ART) and direct-acting antivirals (DAAs) have revolutionized treatment outcomes, persistent issues (including drug resistance, toxicity, poor adherence, limited access in resource-limited settings, and lack of a rapid diagnostic tool) still hamper effective disease control. In coinfected individuals, shared transmission routes and synergistic pathogenesis accelerate liver disease progression and complicate therapeutic management.
Nanotechnology offers innovative solutions across the continuum of care from prevention and early detection to therapeutic intervention. Nanomaterials such as dendrimers, magnetic nanoparticles, liposomes, polymeric micelles, and hybrid nanostructures, and novel nanoplatforms can be engineered to deliver antiviral agents in a targeted and controlled manner, improve pharmacokinetics, enhance patient adherence through long-acting formulations, and integrate biosensing elements for real-time detection of viral proteins, nucleic acids, or host biomarkers. These technologies also hold promise for vaccine delivery, prophylactic strategies, and point-of-care diagnostics, particularly in low-resource settings. This Special Issue invites original research articles, reviews, and perspectives on nanotechnology-enabled strategies for HIV, HCV, and HIV/HCV coinfection. Topics of interest include, but are not limited to:
- Design and engineering of multifunctional nanocarriers for prevention, diagnosis, and therapy
- Long-acting and controlled-release nanomedicines for antiviral delivery
- Integration of diagnostic and therapeutic functionalities in nanoplatforms
- Nanomaterials for vaccine formulation and delivery
- Biopharmaceutical and pharmacokinetic characterization of nano-enabled systems
- Translation from laboratory research to clinical applications in HIV and HCV management
By covering research on HIV alone, HCV alone, or coinfection, this Special Issue aims to provide a comprehensive overview of how advanced pharmaceutical nanotechnology can address urgent unmet needs in the prevention, diagnosis, and management of these high-impact viral diseases.
Dr. Daniel Sepúlveda-Crespo
Dr. Salvador Resino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dendrimers
- diagnostics
- drug resistance
- HCV
- HIV
- HIV/HCV coinfection
- liposomes
- nanocarriers
- nanoparticles
- nanoplatforms
- nanotechnology
- prevention
- targeted drug delivery
- therapeutic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
